Skip to Main Content

Paper Details

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
Nat Commun
39
2021
AKT, HER3, HNSCC, HNSCC cells, HNSCCs, ICB, PD-1, PI3K, PIK3CA, PIK3CA mutations, PIK3CA wild, anti-, cancer, head and neck cancer, head and neck squamous cell carcinoma, mTOR, patients, tumor, tyrosine
Author NameAffiliation
Zhiyong WangMoores Cancer Center, University of California San Diego
Yusuke GotoMoores Cancer Center, University of California San Diego
Michael M AllevatoMoores Cancer Center, University of California San Diego
Michael M AllevatoUniversity of California San Diego
Robert Saddawi-KonefkaMoores Cancer Center, University of California San Diego
Robert Saddawi-Konefkauniversity of california san diego School of Medicine
Mara GilardiMoores Cancer Center, University of California San Diego
Alfredo A MolinoloMoores Cancer Center, University of California San Diego
Alfredo A MolinoloMoores Cancer Center, University of California San Diego
Umamaheswar DuvvuriUniversity of Pittsburgh School of Medicine
Jennifer R GrandisUniversity of California San Francisco
Jennifer R GrandisUniversity of California San Francisco
Joseph A CalifanoMoores Cancer Center, University of California San Diego
Joseph A Califanouniversity of california san diego School of Medicine
Ezra E W CohenMoores Cancer Center, University of California San Diego
Jorge Silvio GutkindMoores Cancer Center, University of California San Diego
Jorge Silvio GutkindUniversity of California San Diego
  • 1 - 17

Datasets